Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$1.57 USD
+0.03 (1.95%)
Updated Sep 13, 2024 09:54 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Compass Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 50 | 42 | 82 | 28 | 34 |
Income After Depreciation & Amortization | -50 | -42 | -82 | -28 | -34 |
Non-Operating Income | 8 | 2 | 0 | -1 | 1 |
Interest Expense | 0 | 0 | 0 | 1 | 1 |
Pretax Income | -42 | -39 | -82 | -29 | -35 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -42 | -39 | -82 | -30 | -35 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -42 | -39 | -82 | -30 | -35 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -41 | -80 | -25 | -32 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -50 | -42 | -82 | -28 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 127.03 | 106.01 | 62.87 | 30.78 | NA |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.37 | -1.31 | -0.96 | NA |
Diluted Net EPS (GAAP) | -0.33 | -0.37 | -1.31 | -0.96 | NA |
Fiscal Year end for Compass Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 15.89 | 12.77 | 15.39 | 11.93 | 13.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.04 | -12.77 | -15.39 | -11.93 | -13.33 |
Non-Operating Income | 1.97 | 1.98 | 1.97 | 1.96 | 2.06 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -13.08 | -10.79 | -13.42 | -9.96 | -11.28 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.08 | -10.79 | -13.42 | -9.96 | -11.28 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -13.08 | -10.79 | -13.42 | -9.96 | -11.28 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 137.59 | 136.61 | 121.96 | 124.55 | 125.31 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.08 | -0.11 | -0.08 | -0.09 |
Diluted Net EPS (GAAP) | -0.10 | -0.08 | -0.10 | -0.08 | -0.09 |